Last 75.15 INR
Change Today 0.00 / 0.00%
Volume 0.0
SVLS On Other Exchanges
Symbol
Exchange
Natl India
As of 7:06 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

suven life sciences ltd (SVLS) Snapshot

Open
74.05
Previous Close
74.65
Day High
75.80
Day Low
74.05
52 Week High
11/12/13 - 83.50
52 Week Low
06/13/13 - 22.00
Market Cap
8.8B
Average Volume 10 Days
685.8K
EPS TTM
0.72
Shares Outstanding
116.8M
EX-Date
08/1/13
P/E TM
103.9x
Dividend
0.30
Dividend Yield
0.40%
Current Stock Chart for SUVEN LIFE SCIENCES LTD (SVLS)

Related News

No related news articles were found.

suven life sciences ltd (SVLS) Related Businessweek News

No Related Businessweek News Found

suven life sciences ltd (SVLS) Details

Suven Life Sciences Limited, a research-based biopharmaceutical company, engages in the design, manufacture, and supply of bulk actives, drug intermediates, and fine chemicals for the life science industry worldwide. The company offers advanced intermediates, intermediates, and active pharmaceutical ingredients. The company also offers contract research and manufacturing services, including development and supply of pharmaceutical and agro chemical intermediates for new chemical entities. In addition, it provides discovery and development of new chemical entities for CNS disorders; research collaborative projects with pharmaceutical companies; and drug discovery research services, including in-vitro screening and molecular biology, drug metabolism and pharmacokinetics, pharmacology, toxicology and genotoxicity, and bioanalysis, as well as operates a formulation development center. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. Suven Life Sciences Limited was founded in 1989 and is based in Hyderabad, India.

Founded in 1989

suven life sciences ltd (SVLS) Top Compensated Officers

Chairman, Chief Executive Officer, Chairman o...
Total Annual Compensation: 9.2M
Wholetime Director, Member of Investor Grieva...
Total Annual Compensation: 4.1M
Compensation as of Fiscal Year 2013.

suven life sciences ltd (SVLS) Key Developments

Suven Life Sciences Grants Exclusive License and Right to Distribute and Market its Malathion Lotion to Taro Pharmaceuticals North America, Inc

Suven Life Sciences has been granted an exclusive license and right to distribute and market its Malathion Lotion USP 0.5% w/v in USA, Canada and Mexico to Taro Pharmaceuticals North America Inc. Malathion lotion is indicated for patients infected with Pediculus humanus capitis (head lice and their ova) of the scalp hair. In consideration for the exclusive license and right to distribute and market Malathion Lotion 0.5% w/v USP in North America, Taro will pay Suven a royalty and the arrangement is effective until April 2028 unless otherwise terminated.

Suven Life Sciences Limited - Special Call

Suven Life Sciences Limited - Special Call

Suven Life Sciences Limited Announces Standalone Unaudited Earnings Results for the Third Quarter and Nine Months Ended December 31, 2013

Suven Life Sciences Limited announced standalone unaudited earnings results for the third quarter and nine months ended December 31, 2013. For the quarter, the company reported total income from operations (net) of INR 1,194.271 million against INR 623.948 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 526.369 million against INR 126.764 million a year ago. Profit from ordinary activities before tax was INR 512.722 million against INR 83.595 million a year ago. Net profit was INR 364.332 million against INR 77.568 million a year ago. Earnings per basic and diluted share were INR 3.12 against INR 0.66 a year ago. Growth in EBIDTA was INR 557 million against INR 152 million a year ago. Pre-R&D EBIDTA was INR 654.65 million against INR 245.32 million a year ago. Pre-R&D Cashflow was INR 484.12 million against INR 192.44 million a year ago. For the nine months, the company reported total income from operations (net) of INR 3,795.090 million against INR 1,831.810 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 1,627.670 million against INR 338.705 million a year ago. Profit from ordinary activities before tax was INR 1,580.683 million against INR 235.690 million a year ago. Net profit was INR 1,117.519 million against INR 222.091 million a year ago. Earnings per basic and diluted share were INR 9.57 against INR 1.90 a year ago. Growth in EBIDTA was INR 1,734 million against INR 401 million a year ago. The growth in profit was a result of prelaunch supplies of 3 products under CRAMS. Pre-R&D EBIDTA was INR 2,090.16 million against INR 649.65 million a year ago. Pre-R&D Cashflow was INR 1,538.82 million against INR 528.04 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SVLS:IN 75.15 INR +0.50

SVLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SVLS.
View Industry Companies
 

Industry Analysis

SVLS

Industry Average

Valuation SVLS Industry Range
Price/Earnings 7.5x
Price/Sales 2.0x
Price/Book 3.9x
Price/Cash Flow 7.0x
TEV/Sales 1.8x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUVEN LIFE SCIENCES LTD, please visit www.suven.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.